Substance / Medication

Vorasidenib

Overview

Active Ingredient
vorasidenib
RxNorm CUI
2690647

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

5
Total Trials
4
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Impact of extent of resection and adjuvant therapy in diffuse gliomas of the spine.
Chalif Eric J, Foster Chase, Sack Kenneth et al. · Spine J · 2023
PMID: 36804437Meta-Analysis
Artificial Intelligence Applications in Glioma With 1p/19q Co-Deletion: A Systematic Review.
Zhang Simin, Yin Lijuan, Ma Lu et al. · J Magn Reson Imaging · 2023
PMID: 37083159Meta-Analysis
Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.
Brandner Sebastian, McAleenan Alexandra, Jones Hayley E et al. · Neuropathol Appl Neurobiol · 2022
PMID: 34958131Meta-AnalysisFull text (PMC)
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.
McAleenan Alexandra, Jones Hayley E, Kernohan Ashleigh et al. · Cochrane Database Syst Rev · 2022
PMID: 35233774Meta-AnalysisFull text (PMC)
Prevalence of seizures in brain tumor: A meta-analysis.
Audrey Christine, Lim Kheng-Seang, Ahmad Zaki Rafdzah et al. · Epilepsy Res · 2022
PMID: 36274423Meta-Analysis
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Mellinghoff Ingo K, Lu Min, Wen Patrick Y et al. · Nat Med · 2023
PMID: 36823302TrialFull text (PMC)
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff Ingo K, van den Bent Martin J, Blumenthal Deborah T et al. · N Engl J Med · 2023
PMID: 37272516TrialFull text (PMC)
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
DiNardo Courtney D, De Botton Stéphane, Pollyea Daniel A et al. · Am J Hematol · 2023
PMID: 37354069Trial
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Mellinghoff Ingo K, Penas-Prado Marta, Peters Katherine B et al. · Clin Cancer Res · 2021
PMID: 34078652TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Vorasidenib (substance)
SNOMED CT
933316181000036101
UMLS CUI
C4726974
RxNorm CUI
2690647

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
5
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.